Bioxcel therapeutics reports third quarter 2020 financial results and provides business update

Complete nda submission for bxcl501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for q1 2021

BTAI Ratings Summary

BTAI Quant Ranking